US Ophthalmic Review


Call for Submissions


Indication: The LenSx® Laser is indicated for use in patients undergoing cataract surgery for removal of the crystalline lens. Intended uses in cataract surgery include anterior capsulotomy, phacofragmentation, and the creation of single plane and multi-plane arc cuts/incisions in the cornea, each of which may be performed either individually or consecutively during the same procedure.


Caution: United States Federal Law restricts this device to sale and use by or on the order of a physician or licensed eye care practitioner. United States Federal Law restricts the use of this device to practitioners who have been trained in the operation of this device.


Restrictions:   


     


   supervision.


Contraindications:    light at 1030 nm wavelength


     


   the capsulotomy


   capsulotomy depth and the endothelium (applicable to capsulotomy only)


   produced by the procedure can escape


        


   abnormality (for example, recurrent corneal erosion, severe basement membrane disease)


     


   


Attention:  and precautions.


Warnings: The LenSx® Laser System should only be operated by a physician trained in its use.


   instrument products constitute a complete surgical system. Use of disposables other  


The physician should base patient selection criteria on professional experience,  undergo cataract extraction.


Precautions:   


  


AEs/Complications:   


   procedure


                       


   www.touchophthalmology.com www.touchophthalmology.com US Ophthalmic Review Volume 4 • Issue 2 • Fall 2011


Management of Ocular Inflammation following Routine Cataract Surgery— Topical Corticosteroid (Prednisolone) versus Topical Non-steroidal (Bromfenac)


Keith A Walter, MD, Amy J Estes, MD, Samantha Watson, BS, MS and Mary Ellingboe, MS


Spectral-domain Optical Coherence Tomography Imaging of Age-related Macular Degeneration


Carlos Alexandre de Amorim Garcia Filho, MD, Philip J Rosenfeld, MD, PhD, Zohar Yehoshua, MD, MHA and Giovanni Gregori, PhD


Vitreoretinal Complications of Phacoemulsification


Steve Charles, MD, FACS, FICS


The Role of Ocular Blood Flow in the Pathogenesis of Glaucomatous Damage


Josef Flammer, MD, Katarzyna Konieczka, MD and Andreas J Flammer, MD


European Ophthalmic Review


Volume 6 • Issue 1 • Spring 2012


Triamcinolone Acetonide for the Treatment of Diabetic Macular Oedema


Valentina Sarao, Daniele Veritti and Paolo Lanzetta


Suprachoroidal Drug Delivery – A New Approach for the Treatment of Severe Macular Diseases


Constanze Augustin, Albert Augustin, Manfred Tetz and Stanislao Rizzo


Nutritional Supplements and Age-related Macular Degeneration – Focus on Omega-3 Fatty Acids


Eric Souied


Imaging Modalities for Uveal Melanoma


Kanish Mirchia, Mary E Turell and Arun D Singh


Special Focus —


Age-related Macular Degenaration


Call for submissions US Ophthalmic Review endeavors to support ophthalmologists in their daily practice through peer-reviewed content, including original contributions, commentaries, review articles and case studies. The journal provides comprehensive discussion and analysis of the latest medical advances and therapeutic options available to ophthalmologists to help diagnose, treat and achieve better patient prognoses.


Join the debate With a focus on all aspects of ophthalmology, including practice management and policy, US Ophthalmic Review is always keen to hear from leading authorities wishing to discuss potential submissions and will give due consideration to all manuscripts submitted.


Manuscripts can be submitted to the journal’s Editor, Misty Gilbert. To download the ‘Instructions to Authors’ information, please visit www.touchophthalmology.com


US Ophthalmic Review Touch Briefings Saffron House, 6–10 Kirby Street, London EC1N 8TS, UK


For further information, please contact Misty Gilbert T: +44 (0) 20 7452 5357 E: misty.gilbert@touchbriefings.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76